Prinoxodan

**Product Data Sheet**

**Cat. No.:** HY-U00208  
**CAS No.:** 111786-07-3  
**Molecular Formula:** C₁₃H₁₃N₄O₂  
**Molecular Weight:** 257.27  
**Target:** Phosphodiesterase (PDE)  
**Pathway:** Metabolic Enzyme/Protease  
**Storage:** Powder  
  -20°C  3 years  
  4°C  2 years  
In solvent  
-80°C  6 months  
-20°C  1 month

**BIOLOGICAL ACTIVITY**

**Description**
Prinoxodan (RGW2938) is a phosphodiesterase inhibitor.

<table>
<thead>
<tr>
<th><strong>IC₅₀ &amp; Target</strong></th>
<th>Phosphodiesterase[¹]</th>
</tr>
</thead>
</table>

**In Vitro**
Prinoxodan (RG W-2938) is an orally effective positive inotropic/vasodilator agent. Prinoxodan is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent is examined in vitro in isolated guinea pig hearts; in the latter, Prinoxodan 5 nmol-5 μmol increases contractility in a dose-related fashion[²].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**In Vivo**
Prinoxodan (RG W-2938) is a new nonglycoside, noncatecholamine cardiotonic/vasodilator agent is examined in vivo in anesthetized and conscious dogs. Prinoxodan 30-300 μg/kg administered intravenously (i.v.) to anesthetized dogs increases contractile force while decreasing arterial pressure and total peripheral resistance (TPR) in a dose-related manner. Heart rate (HR) is only slightly increased, and aortic flow is not appreciably altered. A single oral dose of Prinoxodan 0.3 mg/kg administered to conscious chronically instrumented dogs produces a marked and sustained increase in contractility 15-240 min after treatment while only slightly increasing HR. The effects of Prinoxodan 30-300 μg/kg, i.v. are studied in a mecamylamine-propranolol-induced model of heart failure. Prinoxodan effectively reverses the drug-induced heart failure by increasing myocardial contractility and decreasing arterial pressure while only slightly affecting HR[²].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

**REFERENCES**

